What is Alimera Sciences Operating Cash Flow per Share?
Alimera Sciences's operating cash flow per share for the
three
months ended in Dec. 2023 was $0.07.
Alimera Sciences's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.29.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -9.20% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 12.40% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 31.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Alimera Sciences's Operating Cash Flow per Share or its related term are showing as below:
ALIM'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -17.9 Med: 31.6 Max: 67.8
Current: -9.2
During the past 13 years, Alimera Sciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 67.80% per year. The lowest was -17.90% per year. And the median was 31.60% per year.
ALIM's 3-Year OCF Growth Rate is ranked worse than 73.08% of 806
companies
in the Drug Manufacturers industry
Industry Median: 8.1
vs ALIM: -9.20
Alimera Sciences Operating Cash Flow per Share Historical Data
The historical data trend for Alimera Sciences's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Alimera Sciences Operating Cash Flow per Share Chart
Competitive Comparison of Alimera Sciences's Operating Cash Flow per Share
For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alimera Sciences's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Alimera Sciences's Price-to-Operating-Cash-Flow falls into.
Alimera Sciences Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Alimera Sciences's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.29
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alimera Sciences Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Alimera Sciences's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Alimera Sciences (Alimera Sciences) Business Description
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALIM has been successfully added to your 